Real-world Study on Adjuvant Octreotide Therapy in pNETs
Status:
Completed
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
Adjuvant therapy in pancreatic neuroendocrine tumors (pNETs) after radical resection lacks
evidence-based data and is controversial. Real-world data were clustered to validate whether
the long-acting octreotide is a potential candidate for adjuvant therapy in high recurrence
risk G2 pNET patients.